The promises of Treg
autoimmune therapy,all in one hand
The largest, most advanced pipeline of cell therapies for autoimmune disease.
Company deckAbout PolTREG
Three clinical assets that will deliver value and milestones
PTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis
Leading contender in quest for engineered Tregs
Expects to be first-in-class in launching in-patient trials in CAR-Tregs in MS and Amyotrophic Lateral Sclerosis (ALS)
World-class manufacturing expertise in own facilities
17 years of experience, first company ever to administer Tregs a patient
PolTREG
benefiting patients
Tregs are on their way to become routine treatment for autoimmune diseases and to become a new class of disease-modifying therapeutics.
